Insulet Stock Forecast, Price & News

Insulet (NASDAQ:PODD) Frequently Asked Questions

Is Insulet a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Insulet stock.
View analyst ratings for Insulet or view top-rated stocks.

How has Insulet's stock price been impacted by COVID-19?

Insulet's stock was trading at $172.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PODD stock has increased by 69.9% and is now trading at $292.34.
View which stocks have been most impacted by COVID-19.

When is Insulet's next earnings date?

Insulet is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Insulet.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) announced its earnings results on Thursday, November, 4th. The medical instruments supplier reported $0.18 EPS for the quarter, missing analysts' consensus estimates of $0.25 by $0.07. The medical instruments supplier had revenue of $275.60 million for the quarter, compared to the consensus estimate of $272.62 million. Insulet had a positive trailing twelve-month return on equity of 0.63% and a negative net margin of 2.84%. Insulet's quarterly revenue was up 17.8% on a year-over-year basis. During the same period last year, the firm posted $0.17 EPS.
View Insulet's earnings history.

What guidance has Insulet issued on next quarter's earnings?

Insulet issued an update on its FY 2021 earnings guidance on Thursday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.07 billion-$1.09 billion, compared to the consensus revenue estimate of $1.08 billion.

What price target have analysts set for PODD?

12 equities research analysts have issued 1 year price objectives for Insulet's shares. Their forecasts range from $268.00 to $350.00. On average, they expect Insulet's stock price to reach $311.20 in the next year. This suggests a possible upside of 6.5% from the stock's current price.
View analysts' price targets for Insulet or view top-rated stocks among Wall Street analysts.

Who are Insulet's key executives?

Insulet's management team includes the following people:

• Shacey Petrovic, President, Chief Executive Officer & Director (LinkedIn Profile)
• Charles Alpuche, Chief Operations Officer & Executive VP (LinkedIn Profile)
• Wayde Dwight McMillan, Chief Financial Officer, Treasurer & Executive VP
• Trang Ly, Senior Vice President & Medical Director
• Michael P. Spears, Senior VP-Quality, Regulatory Affairs & Compliance

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet CEO Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among Insulet's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Insulet's key competitors?

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), DexCom (DXCM), IDEXX Laboratories (IDXX), Baxter International (BAX), ResMed (RMD), STERIS (STE), Hologic (HOLX), Masimo (MASI) and Abiomed (ABMD).
View all of PODD's competitors.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), Walt Disney (DIS), salesforce.com (CRM), Roku (ROKU) and Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by a number of retail and institutional investors. Top institutional investors include Capital Research Global Investors (10.49%), Capital World Investors (10.25%), Primecap Management Co. CA (1.99%), Viking Global Investors LP (1.47%), Geode Capital Management LLC (1.26%) and Janus Henderson Group PLC (1.24%). Company insiders that own Insulet stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet.

Which institutional investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, KBC Group NV, Lord Abbett & CO. LLC, Eagle Asset Management Inc., Primecap Management Co. CA, Capital World Investors, Principal Financial Group Inc., and Cubist Systematic Strategies LLC. Company insiders that have sold Insulet company stock in the last year include Bret Christensen, Charles Alpuche, John A Fallon, Sally Crawford, and Shacey Petrovic.
View insider buying and selling activity for Insulet or view top insider-selling stocks.

Which institutional investors are buying Insulet stock?

PODD stock was acquired by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Capital Research Global Investors, Janus Henderson Group PLC, Frontier Capital Management Co. LLC, Bellevue Group AG, Bank of New York Mellon Corp, Geode Capital Management LLC, and Achmea Investment Management B.V..
View insider buying and selling activity for Insulet or or view top insider-buying stocks.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $292.34.

How much money does Insulet make?

Insulet has a market capitalization of $20.16 billion and generates $904.40 million in revenue each year. The medical instruments supplier earns $6.80 million in net income (profit) each year or ($0.45) on an earnings per share basis.

How many employees does Insulet have?

Insulet employs 1,900 workers across the globe.

When was Insulet founded?

Insulet was founded in 2000.

What is Insulet's official website?

The official website for Insulet is www.insulet.com.

Where are Insulet's headquarters?

Insulet is headquartered at 100 NAGOG PARK, ACTON MA, 01720.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at [email protected], or via fax at 978-600-0120.